Recent funding announcements from Eden Research, Isansys Lifecare and Immunocore show how occupiers based at Milton Park are benefitting from an injection of investment and sustained growth.
Eden Research
Eden Research forecasts a 72% increase in full-year revenue for 2023, to £3.1m.
Specialising in sustainable biopesticides and plastic-free formulation technology, the company also foresees a 63% increase in product sales, totalling £2.6 million.
Sean Smith, Chief Executive Officer of Eden Research plc, commented:
“Looking forward, our successful fundraise in 2023 will allow us to expedite the development of our existing product portfolio, expand into new geographies and develop new product opportunities.
“In 2024 we will continue to build on the progress made this year to drive sales growth, step-up commercial activity and push forward apace with our product plans.”
Isansys plays pivotal role in €10 million TARGET project
Occupier Isansys Lifecare plays a crucial role in this data science-enabled healthcare initiative.
With support from the European Union’s Horizon program and the UK Research and Innovation, the project brings together clinical teams, data scientists, physiotherapists, machine learning experts, human factors specialists, patient groups and medical technologists to address a major healthcare challenge that is amongst the commonest causes of death and the leading cause of disability in Europe.
Dr Sandra Ortega, Project Leader and Reader in Data Science at Liverpool John Moore’s University, said: “TARGET will shape cutting-edge virtual twins and AI technologies to develop reliable and personalised models for the benefit and well-being of AF and stroke patients.
These novel AI-based models will further enhance our understanding (causality) of the drivers of disease onset and their impact on disease progression, at the level of the individual, facilitating the exploration and validation of treatments tailored to each patient.
TARGET will pave the way to deliver optimised clinical decision-making and rehabilitation strategies for the AF and stroke patient journey, superior to the current standard of care.”
Immunocore secures $350m in upsized convertible senior notes offering
This financial move from Immunocore reflects strong market demand and will support the occupier’s clinical pipeline acceleration, commercial expansion, and loan repayment.
The company’s focus on advancing healthcare through innovative TCR bispecific immunotherapies is evident in this strategic step, with net proceeds from the offering, together with its existing cash and cash equivalents, intended to accelerate its clinical pipeline and for ongoing commercial expansion.
Sign up to our newsletter
Subscribe